Veronique Fremeaux-Bacchi

List of Publications by Year in Descending Order

71 papers	6,411 citations	35 h-index	76 g-index
76 ext. papers	7,868 ext. citations	8.5 avg, IF	5.36 L-index

#	Paper	IF	Citations
71	Thrombotic microangiopathy with mild renal involvement and profound thrombocytopenia: not all roads lead to thrombotic thrombocytopenic purpura.. *Journal of Nephrology*, **2022**, 1	4.8	
70	Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. *Nature Reviews Nephrology*, **2021**, 17, 543-553	14.9	14
69	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. *Kidney International*, **2021**, 99, 581-597	9.9	15
68	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. *Blood*, **2021**, 137, 2438-2449	2.2	21
67	Atypical HUS relapse triggered by COVID-19. *Kidney International*, **2021**, 99, 267-268	9.9	22
66	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. *Chest*, **2021**, 159, 1884-1893	5.3	6
65	Inherited Kidney Complement Diseases. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 942-956	6.9	8
64	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. *BMC Nephrology*, **2021**, 22, 267	2.7	4
63	COVID-19 as a potential trigger of complement-mediated atypical HUS. *Blood*, **2021**, 138, 1777-1782	2.2	8
62	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. *Frontiers in Immunology*, **2020**, 11, 1772	8.4	5
61	Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease. *Haematologica*, **2020**, 105, 2694-2697	6.6	12
60	C3 glomerulonephritis in a patient treated with anti-PD-1 antibody. *European Journal of Cancer*, **2020**, 125, 46-48	7.5	3
59	Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. *EClinicalMedicine*, **2020**, 28, 100590	11.3	78
58	Complement C5 inhibition in patients with COVID-19 - a promising target?. *Haematologica*, **2020**, 105, 2847-2850	6.6	35
57	Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. *BMC Nephrology*, **2020**, 21, 405	2.7	0
56	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. *Blood*, **2020**, 136, 2103-2117	2.2	23
55	Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies. *Frontiers in Immunology*, **2019**, 10, 1936	8.4	16

54	C3 glomerulopathy - understanding a rare complement-driven renal disease. *Nature Reviews Nephrology*, **2019**, 15, 129-143	14.9	109
53	Complement Gene Variants and Shiga Toxin-Producing -Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 364-377	6.9	20
52	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and□ho□common genetic risk factors. *Kidney International*, **2019**, 95, 1443-1452	9.9	40
51	C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection. *Frontiers in Immunology*, **2019**, 10, 235	8.4	9
50	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. *Haematologica*, **2019**, 104, 2501-2511	6.6	18
49	Autoantibodies Against C3b-Functional Consequences and Disease Relevance. *Frontiers in Immunology*, **2019**, 10, 64	8.4	14
48	Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. *Frontiers in Immunology*, **2019**, 10, 2007	8.4	27
47	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. *British Journal of Clinical Pharmacology*, **2019**, 85, 403-412	3.8	21
46	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. *Journal of Immunology*, **2018**, 200, 2464-2478	5.3	89
45	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and□outcome. *Kidney International*, **2018**, 94, 408-418	9.9	61
44	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. *Frontiers in Immunology*, **2018**, 9, 3008	8.4	23
43	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. *Frontiers in Immunology*, **2018**, 9, 2260	8.4	21
42	Haemolytic uraemic syndrome. *Lancet, The*, **2017**, 390, 681-696	40	246
41	C3 glomerulopathy and eculizumab: a report on four paediatric cases. *Pediatric Nephrology*, **2017**, 32, 1023-1028	3.2	23
40	The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 3066-3075	12.7	40
39	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1237-1247	6.9	104
38	Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies. *Journal of Infectious Diseases*, **2017**, 215, 1331-1338	7	24
37	C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. *American Journal of Kidney Diseases*, **2017**, 70, 834-843	7.4	35

36	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. *Transplantation*, **2017**, 101, 2924-2930	1.8	18
35	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. *Kidney International*, **2017**, 92, 1232-1241	9.9	52
34	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 50-59	6.9	106
33	A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1665-77	12.7	29
32	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatric Nephrology*, **2016**, 31, 15-39	3.2	327
31	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. *Molecular Immunology*, **2016**, 71, 131-142	4.3	84
30	CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). *Pediatric Nephrology*, **2016**, 31, 157-61	3.2	14
29	Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. *Nephrology Dialysis Transplantation*, **2016**, 31, 2122-2130	4.3	56
28	Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody. *American Journal of Kidney Diseases*, **2016**, 68, 944-948	7.4	4
27	The role of complement in C3 glomerulopathy. *Molecular Immunology*, **2015**, 67, 21-30	4.3	65
26	Atypical aHUS: State of the art. *Molecular Immunology*, **2015**, 67, 31-42	4.3	177
25	The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. *Arthritis and Rheumatology*, **2015**, 67, 527-34	9.5	96
24	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood*, **2015**, 125, 2359-69	2.2	79
23	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. *Journal of Biological Chemistry*, **2015**, 290, 25343-55	5.4	31
22	Invasive pneumococcal disease in children can reveal a primary immunodeficiency. *Clinical Infectious Diseases*, **2014**, 59, 244-51	11.6	56
21	Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. *Human Pathology*, **2014**, 45, 2326-33	3.7	12
20	Phenotypic expansion of DGKE-associated diseases. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 1408-14	12.7	50
19	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. *Blood*, **2014**, 123, 121-5	2.2	54

18	Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better. *Kidney International*, **2014**, 85, 1019-22	9.9	9
17	Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. *American Journal of Kidney Diseases*, **2014**, 63, 40-8	7.4	65
16	Complement-binding anti-HLA antibodies and kidney-allograft survival. *New England Journal of Medicine*, **2013**, 369, 1215-26	59.2	594
15	Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. *Nature Genetics*, **2013**, 45, 531-6	36.3	357
14	Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 554-62	6.9	426
13	Eculizumab and drug-induced haemolytic-uraemic syndrome. *CKJ: Clinical Kidney Journal*, **2013**, 6, 484-5	4.5	27
12	Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 475-86	12.7	254
11	Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. *CKJ: Clinical Kidney Journal*, **2013**, 6, 243-4	4.5	26
10	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood*, **2012**, 119, 4182-91	2.2	107
9	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. *Kidney International*, **2012**, 82, 454-64	9.9	360
8	Treatment of atypical uraemic syndrome in the era of eculizumab. *CKJ: Clinical Kidney Journal*, **2012**, 5, 4-6	4.5	8
7	Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. *PLoS Medicine*, **2011**, 8, e1001013	11.6	204
6	Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 2180-7	12.7	199
5	Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 859-67	12.7	320
4	Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. *Kidney International*, **2010**, 77, 339-49	9.9	131
3	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. *Lancet, The*, **2010**, 376, 794-801	40	258
2	Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. *Journal of Medical Genetics*, **2007**, 44, 193-9	5.8	223
1	Recurrence of haemolytic uraemic syndrome after renal transplantation. *Current Opinion in Organ Transplantation*, **2007**, 12, 496-502	2.5	